Hydroxychloroquine for Treatment of SARS-CoV-2 Infection? Improving Our Confidence in a Model-Based Approach to Dose Selection

Clinical and Translational Science

Volumn 13, Issue 4, 2020, Pages 642-645

  Arnold, Samuel L M ^a   Buckner, Frederick ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; HYDROXYCHLOROQUINE; REMDESIVIR;

CHINA; CORONAVIRUS DISEASE 2019; COUGHING; DISEASE SEVERITY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; EC50; FEVER; HUMAN; IN VITRO STUDY; MORTALITY RATE; NONHUMAN; NOTE; PNEUMONIA; PRIORITY JOURNAL; QT PROLONGATION; SEVERE ACUTE RESPIRATORY SYNDROME; TREATMENT DURATION; BETACORONAVIRUS; CORONAVIRUS INFECTION; PANDEMIC; VIRUS PNEUMONIA;

BETACORONAVIRUS; CORONAVIRUS INFECTIONS; HUMANS; HYDROXYCHLOROQUINE; PANDEMICS; PNEUMONIA, VIRAL;

EID: 85083181945     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/cts.12797     Document Type: Note

References (18)

1. Guan, W.J. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708–1720 (2020).
2. Gao, J., Tian, Z. & Yang, X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci. Trends. 14, 72–73 (2020).
3. Yao, X. et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. 2020. https://doi.org/10.1093/cid/ciaa237
4. Gautret, P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents. 2020. https://doi.org/10.1016/j.ijantimicag.2020.105949
5. Wallace, D.J., Gudsoorkar, V.S., Weisman, M.H. & Venuturupalli, S.R. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat. Rev. Rheumatol. 8, 522–533 (2012).
6. Fox, R.I. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin. Arthritis. Rheum. 23, 82–91 (1993).
7. Collins, K.P., Jackson, K.M. & Gustafson, D.L. Hydroxychloroquine: a physiologically-based pharmacokinetic model in the context of cancer-related autophagy modulation. J. Pharmacol. Exp. Ther. 365, 447–459 (2018).
8. Savarino, A., Boelaert, J.R., Cassone, A., Majori, G. & Cauda, R. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis. 3, 722–727 (2003).
9. Vincent, M.J. et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J. 2, 69 (2005).
10. Chen, C.Y., Wang, F.L. & Lin, C.C. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin. Toxicol. (Phila.) 44, 173–175 (2006).
11. O'Laughlin, J.P., Mehta, P.H. & Wong, B.C. Life threatening severe QTc prolongation in patient with systemic lupus erythematosus due to hydroxychloroquine. Case Rep. Cardiol. 2016, 4626279 (2016).
12. Barnard, R.A., Wittenburg, L.A., Amaravadi, R.K., Gustafson, D.L., Thorburn, A. & Thamm, D.H. Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. Autophagy 10, 1415–1425 (2014).
13. McChesney, E.W. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am. J. Med. 75, 11–18 (1983).
14. McChesney, E.W., Banks, W.F. Jr & Fabian, R.J. Tissue distribution of chloroquine, hydroxychloroquine, and desethylchloroquine in the rat. Toxicol. Appl. Pharmacol. 10, 501–513 (1967).
15. French, J.K., Hurst, N.P., O'Donnell, M.L. & Betts, W.H. Uptake of chloroquine and hydroxychloroquine by human blood leucocytes in vitro: relation to cellular concentrations during antirheumatic therapy. Ann. Rheum. Dis. 46, 42–45 (1987).
16. Hamming, I., Timens, W., Bulthuis, M.L., Lely, A.T., Navis, G. & van Goor, H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 203, 631–637 (2004).
17. Tett, S.E., Cutler, D.J., Day, R.O. & Brown, K.F. A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. Br. J. Clin. Pharmacol. 26, 303–313 (1988).
18. Zhou, J. et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J. Infect. Dis. 209, 1331–1342 (2014).